Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage

Clinical Cancer Research

Volumn 10, Issue 20, 2004, Pages 6865-6871

  David, Odile ^a   Jett, James ^b   LeBeau, Helena ^a   Dy, Grace ^b   Hughes, Janet ^a   Friedman, Mitchell ^a   Brody, Arnold R ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; STAINING; SURVIVAL TIME; TISSUE ARRAY; TISSUE SLICE;

CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SURVIVAL ANALYSIS;

EID: 6044230919     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0174     Document Type: Article

References (55)

1. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
2. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001;61:3986-97.
3. Ries LAG, Eisner MP, Kosary CL, et al., editors. SEER cancer statistics review, 1975-2001. Bethesda, MD: National Cancer Institute; 2004. Available from: http://seer.cancer.fob.csr/1975-2001/.
4. American Cancer Society. Cancer facts and figures, 2001; p. 14. Available at: http://www.cancer.org/docroot/STT/stt_0_2001.asp?sitearea=STT&level=1.
5. Swensen SJ, Jett JR, Hartman TE, et al. Lung cancer screening with CT: Mayo Clinic experience. Radiology 2003;226:756-61.
6. Jacobson DR, Fishman CL, Mills NE. Molecular genetic tumor markers in the early diagnosis and screening of non-small-cell lung cancer. Ann Oncol 1995;6:S3-8.
7. Deutsch MA, Pence JC, Kerns BJ, et al. Detection of a novel marker in the bronchial secretions of patients with non-small cell lung cancer using the 4B5 monoclonal antibody. Cancer (Phila) 1992;69:2894-904.
8. Kyogashima M, Mulshine J, Linnoila RI, et al. Antibody 624H12, which detects lung cancer at early stages, recognizes a sugar sequence in the glycosphingolipid difucosylneolactonorhexaosylceramide (V3FucIII3FunLc6Cer). Arch Biochem Biophys 1989;275:309-14.
9. Lacroix J, Becker HD, Woerner SM, et al. Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by preproGRP-specific RT-PCR. Int J Cancer 2001;92:1-8.
10. Mulshine JL, Scott F. Molecular markers in early cancer detection. New screening tools. Chest 1995;107:280S-6S.
11. Tockman MS. Advances in sputum analysis for screening and early detection of lung cancer. Cancer Control 2000;7:19-24.
12. Drevs J, Medinger M, Schmidt-Gersbach C, Weber R, Unger C. Receptor tyrosine kinases: the main targets for new anticancer therapy. Curr Drug Targets 2003;4:113-21.
13. Druker BJ. Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy. Eur J Cancer 2002;38(Suppl 5):S70-6.
14. Davies MA, Koul D, Dhesi H, et al. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 1999;59:2551-6.
15. Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 2001;21:2203-12.
16. Malik SN, Brattain M, Ghosh PM, et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002;8:1168-71.
17. Hsu FD, Nielsen TO, Alkushi A, et al. Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol 2002;15:1374-80.
18. Milanes-Yearsley M, Hammond ME, Pajak TF, et al. Tissue microarray: a cost and time-effective method for correlative studies by regional and national cancer study groups. Mod Pathol 2002;15:1366-73.
19. Freitas S, Moore DH, Michael H, Kelley MR. Studies of apurinic/apyrimidinic endonuclease/ref-1 expression in epithelial ovarian cancer: correlations with tumor progression and platinum resistance. Clin Cancer Res 2003;9:4689-94.
20. 473) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomark Prev 2003;12:660-4.
21. David O. Diagnostic significance of Akt and PTEN in non-small cell lung cancer. Proc Am Assoc Cancer Res 2002;43:754.
22. Brognard J, Dennis PA. Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death Differ 2002;9:893-904.
23. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002;1:707-17.
24. Clark AS, West KA, Blumberg PM, Dennis PA. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res 2003;63:780-6.
25. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 2002;5:234-48.
26. DeLellis RA. Variability in achieving reproducible results in diagnostic immunohistochemistry laboratories. Hum Pathol 1994;25:1109-10.
27. Lee H, Douglas-Jones AG, Morgan JM, Jasani B. The effect of fixation and processing on the sensitivity of oestrogen receptor assay by immunohistochemistry in breast carcinoma. J Clin Pathol 2002;55:236-8.
28. Miller RT, Swanson PE, Wick MR. Fixation and epitope retrieval in diagnostic immunohistochemistry: a concise review with practical considerations. Appl Immunohistochem Mol Morphol 2000;8:228-35.
29. Montera C. The antigen-antibody reaction in immunohistochemistry. J Histochem Cytochem 2003;51:1-4.
30. Werner M, Chott A, Fabiano A, Battifora H. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 2000;24:1016-9.
31. Wester K, Wahlund E, Sundstrom C, et al. Paraffin section storage and immunohistochemistry. Effects of time, temperature, fixation, and retrieval protocol with emphasis on p53 protein and MIB1 antigen. Appl Immunohistochem Mol Morphol 2000;8:61-70.
32. Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 2002;62:7335-42.
33. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002;86:540-5.
34. West KA, Brognard J, Clark AS, et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Investig 2003;111:81-90.
35. Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996;15:6541-51.
36. Brunei A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-68.
37. Rommel C, Clarke BA, Zimmermann S, et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science (Wash DC) 1999;286:1738-41.
38. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science (Wash DC) 1999;286:1741-4.
39. Fukuyama Y, Mitsudomi T, Sugio K, et al. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer 1997;75:1125-30.
40. Huncharek M, Muscat J, Geschwind JF. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis (Lond) 1999;20:1507-10.
41. Lang SM, Stratakis DF, Freudling A, et al. Detection of K-ras and p53 mutations in bronchoscopically obtained malignant and non-malignant tissue from patients with non-small cell lung cancer. Eur J Med Res 2000;5:341-6.
42. Ramakrishna G, Sithanandam G, Cheng RY, et al. K-ras p21 expression and activity in lung and lung tumors. Exp Lung Res 2000;26:659-71.
43. Rosell R, Monzo M, Molina F, et al. K-ras genotypes and prognosis in non-small-cell lung cancer. Ann Oncol 1995;6(Suppl 3):S15-20.
44. Okudela K, Hayashi H, Ito T, et al. K-ras gene mutation enhances motility of immortalized airway cells and lung adenocarcinoma cells via Akt activation: possible contribution to non-invasive expansion of lung adenocarcinoma. Am J Pathol 2004;164:91-100.
45. Kandasamy K, Srivastava RK. Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res 2002;62:4929-37.
46. Itoh N, Semba S, Ito M, et al. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer (Phila) 2002;94:3127-34.
47. Sabbatini P, McCormick F. Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis. J Biol Chem 1999;274:24263-9.
48. Bachelder RE, Ribick MJ, Marchetti A, et al. p53 inhibits alpha 6 beta 4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB. J Cell Biol 1999;147:1063-72.
49. Campbell RA, Bhat-Nakshatri P, Patel NM, et al. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001;276:9817-24.
50. Moore SM, Rintoul RC, Walker TR, et al. The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res 1998;58:5239-47.
51. Nakashio A, Fujita N, Rokudai S, Sato S, Tsuruo T. Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res 2000;60:5303-9.
52. Cuello M, Ettenberg SA, Clark AS, et al. Down-regulation of the erbB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand- mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001;61:4892-900.
53. Zinda MJ, Johnson MA, Paul JD, et al. AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. Clin Cancer Res 2001;7:2475-9.
54. Siegel M. The effectiveness of state-level tobacco control interventions: a review of program implementation and behavioral outcomes. Annu Rev Public Health 2002;23:45-71.
55. Chun KH, Kosmeder JW II, Sun S, et al. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst (Bethesda) 2003;95:291-302.